Background on Stroke Treatment: Revolutionary advances in stroke treatment have occurred over the past two decades from thrombolysis using IV (intravenous) alteplase in the mid-1990's 1,2 to the most recent groundbreaking trials showing the high efficacy of endovascular thrombectomy (EVT) in 2015. 3,4 Studies demonstrate that an additional 10% of patients receiving alteplase within 3 hours of stroke onset will have no disability compared to control, which translates to a number needed to treat (NNT) of 10. 5 EVT is even more efficacious, with studies showing that an additional 14% of patients will have no disability and 20% will be functionally independent (NNT=5). 3 These two synergistic therapies are used to treat acute ischemic stroke, which is the most common type of stroke, making up 85% of all strokes. EVT is provided to a subset of ischemic stroke patients with the most severe form of ischemic stroke due to a large vessel occlusion, while alteplase is appropriate for a larger proportion of ischemic stroke patients including those with both large and small vessel occlusions. Stroke is the leading cause of severe disability, 6 which has significant societal and economic impact. Stroke results in disability that increases the need for assistance with daily living tasks, 7 impedes return to the workplace, 8 and results in high hospital costs. These high hospital costs are related to extended hospitalization during the acute phase, prolonged in-patient rehabilitation, and the need for long-term care. 9 Therefore, because the therapies attenuate the severity of disability, the therapies reduce costs and provide significant societal benefit. Evidence-to-Practice Gap: Although alteplase and EVT are part of guideline care in Canada and around the world, 10,11 less than optimal utilization rates for both of these treatments are observed. This evidence-to-practice gap is not a new phenomenon; 12,13 however, the substantial economic and societal benefits of these therapies make it critical to pursue optimal uptake in Atlantic Canada and the rest of the country. This evidence-practice gap is exacerbated by the geo-political and socio-political divide. There is a split between urban and rural access to treatment. Emergency physicians are less comfortable with intravenous alteplase, 14-16 and they are often the only treating physician in rural hospitals, where access to stroke physicians or neurologists is limited. In fact, the Canadian Association of Emergency Physician only endorsed alteplase in 2015 (revised in 2018) and only to 3 hours after onset. 17 Atlantic Canada is especially challenged by access gaps. The Queen Elizabeth II Health Sciences Centre (QEII) provides guideline-and evidencebased treatment to the residents of metropolitan Halifax, where 22.8% of ischemic stroke patients received alteplase in 2018, but in rural Nova Scotia only 17.5% received alteplase. In New Brunswick, similar discrepancies exist with 15.7% receiving alteplase in Saint John and Moncton, and only 4.8% receiving alteplase outside of th...